The purpose of this study is to investigate the safety and efficacy of the current hard gelatin capsule formulation of NRD135S.E1 80 mg once daily in the treatment of PDPN when administered for 13 weeks.
The purpose of this study is to investigate the safety and efficacy of the current hard gelatin capsule formulation of NRD135S.E1 80 mg once daily in the treatment of PDPN when administered for 13 weeks.
EPPIC-Net: Novaremed Painful Diabetic Peripheral Neuropathy ISA
-
University of California, San Diego, San Diego, California, United States, 92037
South Lake Pain Institute, Clermont, Florida, United States, 34711
SIMEDHealth LLC, Gainesville, Florida, United States, 32607
University of Florida, Gainesville, Florida, United States, 32611
Northwestern Department of Neurology, Chicago, Illinois, United States, 60611
Healthcare Research Network (Flossmoor), Flossmoor, Illinois, United States, 60422
University of Kansas Medical Center, Kansas City, Kansas, United States, 66160
University of Maryland - Baltimore, Baltimore, Maryland, United States, 21201
Johns Hopkins University School of Medicine, Baltimore, Maryland, United States, 21205
MGH Department of Anesthesia, Critical Care, and Pain, Boston, Massachusetts, United States, 02114
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
James P. Rathmell, MD,
Jessica Robinson-Papp, MD, PRINCIPAL_INVESTIGATOR, Icahn School of Medicine at Mount Sinai
2025-01-31